

Vital Link



...For Hoosiers Living with a Bleeding Disorder

March 2025

The Vital Link is published quarterly by
Hemophilia of Indiana, Inc.

Designed by: Kristy McConnell

Board of Directors

President
Joseph McKamey

Vice President
Jason Flora

Treasurer
Corey McSweeney

Secretary
Melissa Breedlove

Directors

Greg Kil
Matt Shade
Jeff Warner

Legal Counsel
Bryce H. Bennett, Jr.

Staff

Scott Ehnes
Executive Director

Kristy McConnell
Development and
Event Director

Angel DiRuzza
Community Outreach
Coordinator

Hemophilia of Indiana
6910 N. Shadeland Ave.
Suite 140
Indianapolis, IN 46220
(317) 570-0039
(800) 241-2873
www.hoii.org

First Quarter Round Up! 2025 Hearts for Hemophilia Gala

The 2025 Hearts for Hemophilia Gala was held February 7th at the beautiful and historic Grand Hall at Union Station. This successful event included a delicious meal, a DJ, casino and photo booth! But more importantly it was one of our highest grossing Galas with the proceeds directly benefitting the programs and services Hemophilia of Indiana provides to the bleeding disorders community! Hemophilia of Indiana would like to thank our special guest speaker, Phil Gatton, CEO of the National Bleeding Disorders Foundation! Thank you to all of the sponsors, donors, and attendees that help make the event such a success! Make sure to check our Facebook page for pictures from the Gala!

2025 NBDF's Washington Days

In early March, an Indiana team headed to Washington DC as part of the National Bleeding Disorders Foundation Washington Days! The Indiana team met with our US Congressional Members and Senators to advocate on behalf of the bleeding disorders community in Indiana and across the country. A special thanks to community member, Vanessa Flora, for the article on pages 2 & 3 to learn more about this year's federal "asks" as well as some important legislation gaining momentum in Indiana!

2025 Bowling for Bleeding Disorders

The 2025 Bowling for Bleeding Disorders event was held on Saturday, March 22nd at Pinheads in Fishers. Over 60 members of our Indiana bleeding disorders community attended the event enjoying a fun afternoon of education and bowling! In addition, attendees were able to meet and talk with our incredible sponsors! Bowling for Bleeding Disorders is also a fundraiser for the Judy Moore Memorial Scholarship Program. Since its inception in 2013, this scholarship program has provided scholarships (open to college undergraduate, graduate, and vocational/trade school students) to over 112 members of Indiana's bleeding disorders community! Please see the article on page 7 for more information!

A Voice for Action

A Voice can Uplift. A Voice can Empower. A Voice can Protect. A Voice can affect Change. As patients and caregivers with rare genetic disorders, our voices are what bring awareness to our communities. Our voices can help to better our treatments and livelihoods. My family has had the amazing opportunity to be sponsored by Hemophilia of Indiana to use our voices for those in the bleeding disorders community. We were invited to Washington Days in 2017 when the Flora boys were in preschool and second grade with their baby sister in a stroller to join other states to advocate and use their voice on behalf of those with bleeding disorders. This event is sponsored by the National Bleeding Disorders Foundation (NBDF) that brings patients and community partners from all over the United States and territories to Washington, D.C. We got to walk across "The Hill", criss-crossing from one building to the next passing by the Capitol to experience the bedrock of political policy. At the time, Congress was considering dismantling the Affordable Care Act, which would have been detrimental to the bleeding disorders community. We had the opportunity to sit across from our elective members in Congress to tell our story about living with hemophilia and how we needed for them to vote to protect those with chronic illnesses. It was such an amazing experience, and we have gone back several times to discuss the most important issues that impact our community.

In March of this year, we traveled back to Washington, D.C. with members of Hemophilia of Indiana and our hemophilia treatment center, Innovative Hematology with three main asks:

1. Support federal health programs (HRSA, CDC, NIH) that support research, safety, and HTC's.
2. Cosponsor the Help Ensure Lower Patient (HELP) Copays Act that allows for copay assistance programs to cover our expensive medications by banning Copay Accumulator Adjustment Policies (CAAPs).
3. Reject health care cuts and policies that create additional red tape and barriers to coverage such as the current proposed Medicaid cuts and to extend the enhanced tax credits for those on ACA Marketplace plans.

Our group underwent training provided by the NBDF before heading out to our congressional "coffee meetings". NBDF had folders and an app to provide all the information and support we needed. All we had to do was to provide our stories. My now teenage son Elias joined me on this last trip and told his story about how important it is to have continued access to his factor and his hemophilia treatment center so he can do the things he enjoys like running for his high school track and cross country teams. I explained how our family relies on copay assistance from our factor manufacturer in order to be able to afford the medication for both boys and myself. We had warm responses from the legislative aides in charge of healthcare policy in the offices of Senators Banks and Young and Representatives Carson and Sparks.

Back home in Indiana, we brought the energy and momentum from our trip in Washington and turned it towards state advocacy. After my visit to Washington in 2024, I reached out to the senator and representative for my district in Indiana to see if we could make some changes at home. Twenty-one states, Puerto Rico, and the District of Columbia have passed state

legislation banning CAAPs due to the stalemate in Washington. I wanted to add Indiana to that same list since I knew my family relies on copay assistance programs AND currently 4 out of 6 Indiana Marketplace plans ban a patient's ability to use copay assistance towards their deductible and out-of-pocket (OOP) maximum. For some patients, this means they have to pay the full amount of their deductible and OOP maximum before they can get their next shipment of medicine. Furthermore, many patients' insurance plans gladly accept co-pay assistance from drug manufacturers but then double dip by still requiring the patient to pay their full deductible and OOP maximum. These insurance practices not only hurt those in the bleeding disorders community because we have no generic drugs, but many in other chronic diseases like cancer, diabetes, and arthritis.

It has been a whirlwind of activity so far at the Indiana Statehouse. With the help of the team from NBDF and community partners, we were able to get bipartisan bills introduced in the Indiana House and Senate. As bills do in government, they ebb and flow as they can become elevated, stagnant, amended, combined, or transformed as they move from one side of government to the other. On March 19th, I used my voice to ban CAAPs as an Amendment to House Bill 1604 in an Indiana Senate Committee meeting flanked by our community partners in the bleeding disorders community, diabetes community, cancer support community, and more. I simply told my story as a woman with and the mother to children with hemophilia. I explained how this Amendment to House Bill 1604 can help to protect my family and other families with bleeding disorders and chronic conditions. As of March 20th, HB 1604 successfully passed out of committee and is headed for final votes before it can be signed into Law. If the law passes, when a patient orders their medications, they will be able to use copay assistance to count toward their deductible and OOP maximum.

We in the bleeding disorders have the opportunity to use our voices to protect ourselves, our families, and others faced with chronic diseases. We can use those voices towards action in policy. You have a voice at every level, even if your voice sometimes feels like a whisper, to tell your story and bring about big changes.

For more information about the current bills in the Indiana Legislature, connect with me on Facebook in our BleedIN Buddies group.

Thank you to Vanessa Flora for her article contribution to the Vital Links Newsletter!!



Indiana's summer camp for children with bleeding disorders and their siblings!



June 8-13, 2025

**YMCA Camp Crosley
North Webster, IN**

Register ASAP to secure your spot at camp!!

<https://www.innovativehematology.org/campbraveeagle/>



Innovative Hematology

Indiana Hemophilia
& Thrombosis Center

**Helping you
thrive with a
bleeding disorder
all in one place**

No matter where you
are in Indiana, we will
extend our care to you.



Innovative Hematology and the IHTC provide care in Indianapolis and across the state through locally based medical professionals, home visits, outreach clinics, and telehealth.

Lifespan bleeding disorder care

Innovative Hematology is home to the Indiana Hemophilia & Thrombosis Center (IHTC), providing advanced care for both adult and pediatric patients with rare bleeding and blood disorders. Our care truly spans a lifetime. There are many changes in life, and our team works to support you through all of them.

The care you need—all in one place

We realize medical appointments take time away from your life. We work to make the most of your visit to decrease the need to go other places for services. Our team, including hematologists, advanced practice providers, mental health professionals, physical therapists, genetic counselors, a nutritionist, and more, are available to you when you need them.

Visit [InnovativeHematology.org](https://www.innovativehematology.org)

Innovative Hematology • 877.CLOTTER
8326 Naab Road • Indianapolis, IN 46260

Take Control of Your Heart Health

By Kristi Dickson, MD – Innovative Hematology

Americans are dying from heart disease more than any other cause including cancer and accidents, according to the Centers for Disease Control.



While this is an alarming fact, many people don't know that heart disease (a general term for weakening of the heart's structure or function) is largely preventable. This is good news, because you can control some of the things that raise your risk of developing heart disease, also known as cardiovascular disease.

Do you smoke?

Are you overweight?

Do you have high blood pressure? High cholesterol? High blood sugar?

I'm a doctor at Innovative Hematology and the IHTC. I see patients who were born with bleeding and blood disorders like hemophilia. People living with hemophilia tend to have higher than average blood pressure - a key risk factor for heart disease.

People can't control disorders they were born with that raise their risk of high blood pressure, and they can't control a family history of heart disease. But people can control other things that raise their risk of heart disease – things like smoking, eating habits, and exercise levels. Working to improve their lifestyle can help people lower their risk of life-threatening events like heart attacks, strokes, and circulation problems.

Getting older also raises your risk of heart disease. Why not control what you can?

- Quit smoking
- Exercise regularly
- Eat a healthy diet
- Get enough quality sleep
- Maintain a healthy weight
- Talk with your doctor about your
 - » Blood pressure
 - » Cholesterol
 - » Blood sugar
 - » Family health history

The American Heart Association has tips for lifestyle changes that help lower the risk of heart disease and gives information about heart attacks and strokes. Visit www.heart.org for more information.

Introducing Innovative Hematology/IHTC's Cardiovascular Disease Risk Reduction Program

Innovative Hematology and the Indiana Hemophilia & Thrombosis Center (IHTC) are excited to announce our new Cardiovascular Disease Risk Reduction Program.

Cardiovascular disease (CVD) is also known as heart disease. The goal of this program is to reduce patients' risk of CVD. Patients with Hemophilia can have a higher risk of CVD.

Learn more here:



Meet Dr. Kristi Dickson

Dr. Kristi Dickson is an internal medicine physician at Innovative Hematology and the Indiana Hemophilia & Thrombosis Center in Indianapolis. Dr. Dickson specializes in primary care and lifestyle medicine and helps her patients avoid or manage health problems, keeping their bleeding and blood disorders in mind.



Innovative Hematology
Indiana Hemophilia
& Thrombosis Center

8326 Naab Road,
Indianapolis, IN 46260
Tel: 317.871.0000
innovativehematology.org

2025 SCHOLARSHIP OPPORTUNITIES!!!

Applications are now being accepted for the 2025/2026 Judy Moore Memorial Scholarship and the 2025/2026 Ed Magoni Memorial Scholarship. Application forms and instructions can be found under the Member Resources tab on Hemophilia of Indiana's website:

(www.hoii.org/member-resources/scholarships).

Scholarships will be awarded to those inflicted with a bleeding disorder, including but not limited to von Willebrand's disease, Hemophilia A, or Hemophilia B. The scholarship will be presented to the applicants that provides the best combination of a creative and persuasive essay, excellent recommendations, and superior academic standing.

Submission deadline for both scholarships is May 28, 2025.

Additional links to other scholarship opportunities can also be found on the above webpage. Contact Angel DiRuzza at 317-570-0039 or adiruzza@hoii.org with any questions.



HEMOPHILIA
OF INDIANA

Women's Retreat

WHERE THERE IS A WOMAN
THERE IS A MIRACLE

May 17th & 18th

Renaissance Indianapolis North Hotel
Carmel, IN

For more information go to <https://hoii.org/womens-retreat/>

Alhemo® is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A with Factor 8 inhibitors or hemophilia B with Factor 9 inhibitors. It is not known if Alhemo® is safe and effective in people using Alhemo® while receiving ongoing immune tolerance induction. It is not known if Alhemo is safe and effective for hemophilia A and B with and without inhibitors in children younger than 12 years of age.


Reimagined bleed protection is now within your reach

First and only prophylaxis treatment in a prefilled, subcutaneous pen for people who have hemophilia B with inhibitors or hemophilia A with inhibitors

NOW APPROVED

Alhemo®
concizumab-mtci
Injection | 60 mg | 150 mg | 300 mg pens

Royal lives with hemophilia B with inhibitors, uses Alhemo®, and is an employee of Novo Nordisk.



NO
IV infusions



NO
mixing



NO
vials



NO
refrigeration required^a
(up to 4 weeks after first use)

Needles provided separately and may require a prescription in some states.

^aStore in refrigerator before first use. After first use, Alhemo® can be stored at room temperature below 86 °F (30 °C) or in a refrigerator at 36 °F to 46 °F (2 °C to 8 °C) for up to 4 weeks.
IV=intravenous.

Important Safety Information

What is the most important information I should know about Alhemo®?

- **It is important to follow the daily dosing schedule of Alhemo® to stay protected against bleeding.** This is especially important during the first 4 weeks of treatment to make sure a correct maintenance dose is established. Use Alhemo® exactly as prescribed by your healthcare provider (HCP). **Do not** stop using Alhemo® without talking to your HCP. If you miss doses or stop using Alhemo®, you may no longer be protected against bleeding
- **Your HCP may prescribe bypassing agents during treatment with Alhemo®.** Carefully follow your HCP's instructions regarding when to use on-demand bypassing agents, and the recommended dose and schedule for breakthrough bleeds

Do not use Alhemo® if you are allergic to concizumab-mtci or any of the ingredients in Alhemo®.

Before using Alhemo®, tell your HCP about all of your medical conditions, including if you:

- Have a planned surgery. Your HCP may stop treatment with Alhemo® before your surgery. Talk to your HCP about when to stop using Alhemo® and when to start it again if you have a planned surgery
- Are pregnant or plan to become pregnant. It is not known if Alhemo® may harm your unborn baby

Females who are able to become pregnant

- Your HCP may do a pregnancy test before you start treatment with Alhemo®.
- You should use an effective birth control (contraception) method during treatment with Alhemo® and for 7 weeks after ending treatment. Talk to your HCP about birth control methods that you can use during this time
- Are breastfeeding or plan to breastfeed. It is not known if Alhemo® passes into your breast milk. Talk to your HCP about the best way to feed your baby during treatment with Alhemo®

Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your HCP and pharmacist when you get a new medicine.

How should I use Alhemo®?

- Change (rotate) your injection site with each injection. **Do not** use the same site for each injection
- To determine the right maintenance dose for you, your HCP will do a blood test to check the amount of Alhemo® in your blood. Your HCP may do additional blood tests during treatment with Alhemo®
- Do not share your Alhemo® pens and needles with another person, even if the needle has been changed. You may give another person an infection or get an infection from them
- **If you miss a dose of Alhemo® during the first 4 weeks of treatment**, contact your HCP right away. Your HCP will tell you how much Alhemo® to inject

What are the possible side effects of Alhemo®?

Alhemo® may cause serious side effects, including:

- **Blood clots (thromboembolic events).** Alhemo® may cause blood clots to form in blood vessels, such as in your arms, legs, heart, lung, brain, eyes, kidneys, or stomach. You may be at risk for getting blood clots during treatment with Alhemo® if you use high or frequent doses of factor products or bypassing agents to treat breakthrough bleeds, or if you have certain conditions. Get medical help right away if you have any signs and symptoms of blood clots, including: swelling, warmth, pain, or redness of the skin; headache; trouble speaking or moving; eye pain or swelling; sudden pain in your stomach or lower back area; feeling short of breath or severe chest pain; confusion; numbness in your face; and problems with your vision
- **Allergic reactions.** Alhemo® can cause allergic reactions, including redness of the skin, rash, hives, itching, and stomach-area (abdominal) pain. Stop using Alhemo® and get emergency medical help right away if you develop any signs or symptoms of a severe allergic reaction, including: itching on large areas of skin; trouble swallowing; wheezing; pale and cold skin; dizziness due to low blood pressure; redness or swelling of lips, tongue, face, or hands; shortness of breath; tightness of the chest; and fast heartbeat

The most common side effects of Alhemo® include: bruising, redness, bleeding, or itching at the site of injection, and hives.

Please see Brief Summary of Prescribing Information on the following page.



Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536 U.S.A.
Alhemo® is a registered trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2025 Novo Nordisk Printed in the U.S.A. US24AHM00028 January 2025

Ready to discover more?

Ask your doctor about Alhemo® or visit **Alhemo.com** by scanning the QR Code





Brief Summary of information about Alhemo® (concizumab-mtci) injection

Rx Only

This information is not comprehensive.

- Talk to your healthcare provider or pharmacist
- Visit www.novo-pi.com/alhemo.pdf to obtain FDA-approved product labeling
- Call 1-888-668-6732

What is the most important information I should know about Alhemo®?

- **It is important to follow the daily dosing schedule of Alhemo® to stay protected against bleeding.** This is especially important during the first 4 weeks of treatment to make sure a correct maintenance dose is established. Use Alhemo® exactly as prescribed by your healthcare provider. **Do not** stop using Alhemo® without talking to your healthcare provider. If you miss doses, or stop using Alhemo®, you may no longer be protected against bleeding.
- **Your healthcare provider may prescribe bypassing agents during treatment with Alhemo®.** Carefully follow your healthcare provider's instructions regarding when to use on-demand bypassing agents, and the recommended dose and schedule for breakthrough bleeds.

See "How should I use Alhemo®?" for more information on how to use Alhemo®.

What is Alhemo®?

Alhemo® is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A with factor VIII inhibitors or hemophilia B with factor IX inhibitors.

It is not known if Alhemo® is safe and effective in people using Alhemo® while receiving ongoing Immune Tolerance Induction (ITI).

It is not known if Alhemo® is safe and effective for hemophilia A and B with and without inhibitors in children younger than 12 years of age.

Do not use Alhemo® if you are allergic to concizumab-mtci or any of the ingredients in Alhemo®.

Before using Alhemo®, tell your healthcare provider about all of your medical conditions, including if you:

- have a planned surgery. Your healthcare provider may stop treatment with Alhemo® before your surgery. Talk to your healthcare provider about when to stop using Alhemo® and when to start it again if you have a planned surgery.
- are pregnant or plan to become pregnant. It is not known if Alhemo® may harm your unborn baby. **Females who are able to become pregnant**
 - Your healthcare provider may do a pregnancy test before you start treatment with Alhemo®.
 - You should use an effective birth control (contraception) during treatment with Alhemo® and for 7 weeks after ending treatment. Talk to your healthcare provider about birth control methods that you can use during this time.
- are breastfeeding or plan to breastfeed. It is not known if Alhemo® passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with Alhemo®.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

How should I use Alhemo®?

- Use Alhemo® exactly as prescribed by your healthcare provider.
- Your healthcare provider will provide instructions for stopping (discontinuing) your current treatment when switching to Alhemo®.
- Inject Alhemo® 1 time a day.
- **Your healthcare provider should show you or your caregiver how to use Alhemo® before you use it for the first time.**
- Alhemo® is given as an injection under the skin (subcutaneous injection) by you or a caregiver.
- Ask your healthcare provider if you need to use a different injection technique. For example, children and people who are lean may need to inject into a pinched fold of skin to avoid injecting too deep (into the muscle).
- Change (rotate) your injection site with each injection. **Do not** use the same site for each injection.
- You will inject a larger dose (a loading dose) of Alhemo® on your first day of treatment. Then your healthcare provider will prescribe a dose to inject 1 time a day until your maintenance dose is established.
- To determine the right maintenance dose for you, your healthcare provider will do a blood test to check the amount of Alhemo® in your blood. Your healthcare provider may do additional blood tests during treatment with Alhemo®.
- Your healthcare provider will prescribe your dose based on your weight. If your weight changes, tell your healthcare provider.

How should I use Alhemo®? (cont'd)

- Your healthcare provider will provide information on the treatment of breakthrough bleeding during your treatment with Alhemo®.
- Do not share your Alhemo® pens and needles with another person, even if the needle has been changed. You may give another person an infection or get an infection from them.
- **If you miss a dose of Alhemo® during the first 4 weeks of treatment**, contact your healthcare provider right away. Your healthcare provider will tell you how much Alhemo® to inject.
- **If you miss a dose of Alhemo® after your daily maintenance dose is established:**
 - For 1 missed dose, continue your normal daily dose.
 - For 2 to 6 missed doses, give 2 doses as soon as you remember. Then continue your normal daily dose the next day.
 - For 7 or more missed doses, contact your healthcare provider right away as you will need to receive a new loading dose before continuing your normal daily dose.
 - If you are unsure about how much to Alhemo® to inject, contact your healthcare provider.

What are the possible side effects of Alhemo®?

Alhemo® may cause serious side effects, including:

- **Blood clots (thromboembolic events).** Alhemo® may cause blood clots to form in blood vessels, such as in your arms, legs, heart, lung, brain, eyes, kidneys, or stomach. You may be at risk for getting blood clots during treatment with Alhemo® if you use high or frequent doses of factor products or bypassing agents to treat breakthrough bleeds, or if you have certain conditions. Get medical help right away if you have any signs and symptoms of blood clots, including:
 - swelling, warmth, pain, or redness of the skin
 - headache
 - trouble speaking or moving
 - eye pain or swelling
 - sudden pain in your stomach or lower back area
 - feeling short of breath or severe chest pain
 - confusion
 - numbness in your face
 - problems with your vision
- **Allergic reactions.** Alhemo® can cause allergic reactions, including redness of the skin, rash, hives, itching, and stomach-area (abdominal) pain. Stop using Alhemo® and get emergency medical help right away if you develop any signs or symptoms of a severe allergic reaction, including:
 - itching on large areas of skin
 - trouble swallowing
 - wheezing
 - pale and cold skin
 - dizziness due to low blood pressure
 - redness or swelling of lips, tongue, face, or hands
 - shortness of breath
 - tightness of the chest
 - fast heartbeat

The most common side effects of Alhemo® include:

- bruising, redness, bleeding, or itching at the site of injection
- hives

These are not all the possible side effects of Alhemo®.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store Alhemo®?

- **Before first use:**
 - Store unused Alhemo® pens in the refrigerator between 36°F to 46°F (2°C to 8°C).
- **After first use:**
 - Store the Alhemo® pen in the refrigerator between 36°F to 46°F (2° to 8°C) or at room temperature below 86°F (30°C) for up to 28 days.
 - Write the date of first use in the space provided on the carton.
 - Throw away (discard) the Alhemo® pen 28 days after first opening even if some medicine is left in the pen.
- Store Alhemo® with the cap on and keep it in the original carton to protect from light.
- Do not store Alhemo® in direct sunlight and keep away from direct heat.
- When stored in the refrigerator, do not store the pen directly next to the cooling element (the part that cools the refrigerator).
- Do not freeze Alhemo®.
- Do not use Alhemo® if it has been frozen or if it has been stored above 86°F (30°C).

Keep Alhemo® and all medicine out of the reach of children.

More detailed information is available upon request.

Available by prescription only.

For information contact: Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536, USA, 1-888-668-6444

Manufactured by: Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, NJ 08536 U.S. License No. 1261

At: Novo Nordisk A/S, Novo Allé 1, 2880 Bagsværd, Denmark

Alhemo® is a registered trademark of Novo Nordisk Health Care AG.

© 2024 Novo Nordisk US24AHM00199 January 2025





Scan the QR code to sign up for updates at [HYMPAVZI.com](https://www.HYMPAVZI.com)

For routine prophylaxis in patients 12 years and older with hemophilia A or B without inhibitors

NOW APPROVED

Introducing HYMPAVZI—a once-weekly subcutaneous prophylactic treatment that comes in a fixed-dose,* prefilled pen

*Your first dose (loading dose) of HYMPAVZI is 300 mg (two 150 mg injections). Then you will inject a weekly (maintenance) dose consisting of 1 or 2 injections as prescribed by your healthcare provider. If more than one injection is required to deliver a complete dose, administer each injection at a different injection site.

What is HYMPAVZI?

HYMPAVZI is a prescription medicine used to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors.

It is not known if HYMPAVZI is safe and effective in children younger than 12 years old.

IMPORTANT SAFETY INFORMATION

Important: Before you start using HYMPAVZI, it is very important to talk to your healthcare provider about using factor VIII and factor IX products (products that help blood clot but work in a different way than HYMPAVZI). You may need to use factor VIII or factor IX medicines to treat episodes of breakthrough bleeding during treatment with HYMPAVZI. Carefully follow your healthcare provider's instructions regarding when to use factor VIII or factor IX medicines and the prescribed dose during your treatment with HYMPAVZI.

Before using HYMPAVZI, tell your healthcare provider about all of your medical conditions, including if you:

- have a planned surgery. Your healthcare provider may stop treatment with HYMPAVZI before your surgery. Talk to your healthcare provider about when to stop using HYMPAVZI and when to start it again if you have a planned surgery.
- have a severe short-term (acute) illness such as an infection or injury.
- are pregnant or plan to become pregnant. HYMPAVZI may harm your unborn baby.

Females who are able to become pregnant:

- Your healthcare provider will do a pregnancy test before you start your treatment with HYMPAVZI.
- You should use effective birth control (contraception) during treatment with HYMPAVZI and for at least 2 months after the last dose of HYMPAVZI.
- Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with HYMPAVZI.
- are breastfeeding or plan to breastfeed. It is not known if HYMPAVZI passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of HYMPAVZI?

HYMPAVZI may cause serious side effects, including:

- **blood clots (thromboembolic events).** HYMPAVZI may increase the risk for your blood to clot. Blood clots may form in blood vessels in your arm, leg, lung, or head and can be life-threatening. Get medical help right away if you develop any of these signs or symptoms of blood clots: swelling or pain in arms or legs; redness or discoloration in your arms or legs; shortness of breath; pain in chest or upper back; fast heart rate; cough up blood; feel faint; headache; numbness in your face; eye pain or swelling; trouble seeing
- **allergic reactions.** Allergic reactions, including rash and itching have happened in people treated with HYMPAVZI. Stop using HYMPAVZI and get medical help right away if you develop any of the following symptoms of a severe allergic reaction: swelling of your face, lips, mouth, or tongue; trouble breathing; wheezing; dizziness or fainting; fast heartbeat or pounding in your chest; sweating

The most common side effects of HYMPAVZI are injection site reactions, headache, and itching.

These are not all the possible side effects of HYMPAVZI. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.


Please see Important Facts about HYMPAVZI on the next page or at www.HYMPAVZI.com



Not actual size.



IMPORTANT FACTS



Important information: Before you start using HYMPAVZI, it is very important to talk to your healthcare provider about using factor VIII and factor IX products (products that help blood clot but work in a different way than HYMPAVZI). You may need to use factor VIII or factor IX medicines to treat episodes of breakthrough bleeding during treatment with HYMPAVZI. Carefully follow your healthcare provider's instructions regarding when to use factor VIII or factor IX medicines and the prescribed dose during your treatment with HYMPAVZI.

What is HYMPAVZI used for?

HYMPAVZI is a prescription medicine used to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors.

It is not known if HYMPAVZI is safe and effective in children younger than 12 years old.

What should I tell my healthcare provider before using HYMPAVZI?

Tell your healthcare provider about all your medical conditions, including if you:

- have a planned surgery. Talk to your healthcare provider about when to stop using HYMPAVZI and when to start it again if you have a planned surgery.
- have a severe short-term (acute) illness such as an infection or injury.
- are pregnant or plan to become pregnant. HYMPAVZI may harm your unborn baby.

Females who are able to become pregnant:

- Your healthcare provider will do a pregnancy test before you start your treatment with HYMPAVZI.
- You should use effective birth control (contraception) during treatment with HYMPAVZI and for 2 months after the last dose of HYMPAVZI.
- Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with HYMPAVZI.
- are breastfeeding or plan to breastfeed. It is not known if HYMPAVZI passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements.

How should I use HYMPAVZI?

See the detailed "Instructions for Use" that comes with your HYMPAVZI for information on how to inject a dose of HYMPAVZI, and how to properly throw away (dispose of) used HYMPAVZI prefilled syringe or HYMPAVZI prefilled pen.

- Use HYMPAVZI exactly as prescribed by your healthcare provider.
- Your healthcare provider will provide information on the treatment of breakthrough bleeding during your treatment with HYMPAVZI. **Do not** use HYMPAVZI to treat breakthrough bleeding.

What warnings should I know about HYMPAVZI?

HYMPAVZI may cause serious side effects, including:

- **blood clots (thromboembolic events).** HYMPAVZI may increase the risk for your blood to clot in blood vessels in your arm, leg, lung, or head and can be life-threatening. Get medical help right away if you develop any of these signs or symptoms of blood clots:

- swelling or pain in arms or legs
- redness or discoloration in your arms or legs
- shortness of breath
- pain in chest or upper back
- fast heart rate
- cough up blood
- feel faint
- headache
- numbness in your face
- eye pain or swelling
- trouble seeing

- **allergic reactions.** Allergic reactions, including rash and itching have happened in people treated with HYMPAVZI. Stop using HYMPAVZI and get medical help right away if you develop any of the following symptoms of a severe allergic reaction:

- swelling of your face, lips, mouth, or tongue
- trouble breathing
- wheezing
- dizziness or fainting
- fast heartbeat or pounding in your chest
- sweating

The most common side effects of HYMPAVZI are injection site reactions, including:

- itching
- swelling
- hardening
- redness
- bruising
- pain

Headache and itching were also common side effects. A serious side effect of swelling in the legs happened in one patient in the clinical trial.

These are not all of the possible side effects of HYMPAVZI. Call your doctor for medical advice about side effects. For more information, ask your doctor.

This information is not comprehensive. How to get more information:

- Talk to your health care provider or pharmacist
- Visit www.HYMPAVZI.com to obtain the FDA-approved product labeling
- Call 1-888-HYMPAV-Z

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.



Pfizer Inc., 66 Hudson Blvd East, New York, NY 10001

© 2024 Pfizer Inc. HYMPAVZI is a trademark of Pfizer Inc. All rights reserved. October 2024 PP-HYM-USA-0057



6910 N. Shadeland Ave., Suite 140
Indianapolis, IN 46220
www.hoii.org
(317) 570-0039

NON PROFIT ORG.
U.S. POSTAGE
PAID
PERMIT NO. 2680
INDPLS., IN

*The material provided in Vital Link is only for general information purposes. HoII does not give medical advice or engage in the practice of medicine. HoII recommends in all cases that you consult your physician or HTC before pursuing any course of treatment.

Mark your Calendars!

- 2025 Women's Retreat - May 17th & 18th
- 2025 Camp Brave Eagle - June 8th - 13th
- 2025 Course to a Cure - June 13th

Call our office @ (317) 570-0039 or email Kristy McConnell @ kmcconnell@hoii.org if you would like to get involved in any of our events!

- Check out our social media pages for updates!!!

